Monograph

C03CA04 - Torasemide

Possibly porphyrinogenic

Rationale

Metabolised by CYP2C9. Torasemide is a sulfonamide congener, drug group often incriminated in porphyric attacks. One reference warns against the drug on grounds of insufficient data.

Chemical description

Sulfonamide congener.

Therapeutic characteristics

Sulfonamide loop-diuretic.

Metabolism and pharmacokinetics

Extensively CYP-metabolized in the liver, CYP2C9 is probably the most important isoenzyme. No data pointing to CYP-induction.

Personal communication

None

Published experience

None

IPNet drug reports

Uneventful use reported in 2 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C03C / C03CA or go back.

References

#	Citation details	PMID
*	Scientific articles
1.	Torasemide. A review of its pharmacological properties and therapeutic potential. Friedel HA, Buckley MM. Drugs. 1991 Jan;41(1):81-103.	1706990
2.	Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Miners JO, Coulter S, Birkett DJ, Goldstein JA. Pharmacogenetics. 2000 Apr;10(3):267-70.	10803683
3.	Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. J Pharmacol Exp Ther. 1995 Mar;272(3):1076-81.	7891318

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames